Assessing Hepatic Impairment with Biomarker-informed Physiologically-based Pharmacokinetic Modelling (BI-PBPK): Strengths and Limitations of the Endogenous Biomarker Coproporphyrin-I评估肝脏损伤与生物标志物指导的生理学基础药代动力学模型(BI-PBPK):内源性生物标志物粪卟啉-I的优缺点Drug Metabolism and DispositionIF42025-11-280PRE
Applications of the Cholesterol Metabolite, 4β-Hydroxycholesterol, as a Sensitive Endogenous Biomarker for Hepatic CYP3A Activity Evaluated within a PBPK FrameworkPHARMACEUTICSIF5.52024-09-300OAAI
Quantification of Proteins Involved in Intestinal Epithelial Handling of XenobioticsCLINICAL PHARMACOLOGY & THERAPEUTICSIF5.52020-12-0526OAAI
The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat ModelJOURNAL OF PHARMACEUTICAL SCIENCESIF3.82017-09-0122OAAI
Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactionsEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCESIF4.72016-06-0198OAAI
Breast Cancer Resistance Protein Abundance, but Not mRNA Expression, Correlates With Estrone-3-Sulfate Transport in Caco-2JOURNAL OF PHARMACEUTICAL SCIENCESIF3.82016-04-017PREAI
Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT techniqueJOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSISIF3.12015-06-0155OAAI
In vivo methods for drug absorption - Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effectsEUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCESIF4.72014-06-01228PREAI
Alternative Fusion Protein Strategies to Express Recalcitrant QconCAT Proteins for Quantitative Proteomics of Human Drug Metabolizing Enzymes and TransportersJOURNAL OF PROTEOME RESEARCHIF3.62013-10-3162PRE